首页 | 本学科首页   官方微博 | 高级检索  
检索        

血脂康对大鼠心肌缺血再灌注损伤的保护作用
引用本文:张雪娟,聂毛晓,滕蕾.血脂康对大鼠心肌缺血再灌注损伤的保护作用[J].中国药学杂志,2010,45(13):1002-1004.
作者姓名:张雪娟  聂毛晓  滕蕾
作者单位:青岛大学医学院附属医院心内科,山东 青岛 266003
摘    要: 目的 观察血脂康预处理对大鼠急性心肌缺血再灌注损伤的保护作用,探讨血脂康的保护作用机制。方法 健康Wistar大鼠32只,体重200~250 g,随机分为4组,即正常对照组、假手术组、缺血再灌注损伤组、血脂康预处理组。建立大鼠急性心肌缺血再灌注损伤模型,在实验终点于腹腔静脉采血,分离血清,检测白细胞介素1-β(IL-1β)、白细胞介素-4(IL-4)、肌酸激酶同工酶(CK-MB)和肌钙蛋白I(TNI)的含量,并处死动物取出心脏,计算梗死心肌面积。结果 血脂康组与缺血再灌注组IL-1β、CK-MB及TNI含量均明显高于正常对照组和假手术组(P<0.01);而血脂康组IL-1β、CK-MB及TNI含量均显著低于缺血再灌注组(P<0.05),血脂康组IL-4水平明显高于缺血再灌注组(P<0.05),心肌梗死面积明显小于缺血再灌注组(P<0.05)。结论 血脂康可能通过抑制促炎因子IL-1β、增加抗炎因子IL-4含量,减轻缺血再灌注时的炎症反应,减少心肌缺血再灌注损伤,对缺血再灌注损伤具有明显的保护作用。

关 键 词:血脂康  缺血再灌注损伤  白细胞介素-1β  白细胞介素-4  肌酸激酶同工酶  肌钙蛋白I
收稿时间:2012-01-01;

Protective Effects of Xuezhikang on Myocardial Ischemia-Reperfusion Injury in Rats
ZHANG Xue-juan,NIE Mao-xiao,TENG Lei.Protective Effects of Xuezhikang on Myocardial Ischemia-Reperfusion Injury in Rats[J].Chinese Pharmaceutical Journal,2010,45(13):1002-1004.
Authors:ZHANG Xue-juan  NIE Mao-xiao  TENG Lei
Institution:Department of Cardiology, Affiliated Hospital of Qingdao Medical University, Qingdao 266003, China
Abstract:OBJECTIVE To investigate the protective effects of Xuezhikang and its mechanisms on myocardial ischemia reperfusion injury(MIRI) in rats. METHODS Thirty-two Wistar rats were randomized into four groups, such as normal group, sham group,ischemia reperfusion injury group and Xuezhikang preconditioning group. The MIRI model was built. Blood samples were collected from the abdominal vein of the animals,and the serum was collected for the measurement of interleukin-1β,interleukin-4,creatine kinase-MB (CK-MB),and troponinI. MI size was determined by Evans Blue staining. RESULTS In ischemia reperfusion injury group and Xuezhikang preconditioning groups,the levels of serum IL-1β, CK-MB and TNI were higher significantly than those in normal group and sham group(P<0.01). Compared with ischemia reperfusion injury group, the levels of the serum IL-1β, CK-MB, TNI and areas of myocardial infarction were decreased significantly in Xuezhikang preconditioning groups(P<0.05). The levels of IL-4 in Xuezhikang preconditioning groups were higher significantly than those in ischemia reperfusion injury group(P<O.05). CONCLUSION Xuezhikang can protect myocardial from ischemia reperfusion injury by reducing serum IL-1β and enhancing serum IL-4 and reducing systemic inflammatory responses.
Keywords:Xuezhikang  myocardial ischemia reperfusion injury  interleukin-1β  interleukin-4  creatine kinase-MB  troponinI
点击此处可从《中国药学杂志》浏览原始摘要信息
点击此处可从《中国药学杂志》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号